Diagnostics fuel growth but nutrition and debt add drag
- Exact Sciences added $1.0 billion in sales during the second quarter.
- Medical Devices grew 8.0 percent excluding foreign exchange in the first half of 2026.
- Nutrition reversed its earlier recovery, falling 5.6 percent in the first half of 2026.
- Libre Duo received a CE Mark in Europe to track both glucose and ketones.
- U.S. Structural Heart sales lagged internal goals due to commercial execution challenges.
A stronger mix with new brakes
Abbott is still led by Medical Devices. The segment grew 8.0 percent in the first half of 2026, excluding foreign exchange. Rhythm Management, Electrophysiology, and Heart Failure grew at double-digit rates. Diabetes Care also grew 8.2 percent, and Abbott secured a CE Mark for Libre Duo in Europe to track both glucose and ketones.
The Exact Sciences deal gives Abbott a massive new cancer testing business. Cancer Diagnostics added about $1.0 billion in sales during the second quarter alone. This makes Abbott a major player in oncology testing and offsets weakness in respiratory virus testing.
The worry list is real. Abbott issued about $20 billion of long-term debt to fund Exact Sciences. The Nutrition business failed to sustain its sequential recovery, posting a 5.6 percent decline in the first half of 2026 due to lower volumes. U.S. Structural Heart also has a commercial execution problem, and management expects the fix to take time.
Finn maintains a balanced view. Abbott has several strong growth lanes, but the next step depends on timing. Investors need to watch Libre reimbursement, Exact Sciences profit margins, and a U.S. Structural Heart recovery.
Many healthcare baskets
Abbott makes money by selling healthcare products to hospitals, labs, pharmacies, distributors, governments, and consumers. The company reports four main segments: Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products.
Medical Devices is the biggest segment. Its growth depends on better technology, doctor adoption, insurance coverage, and Abbott winning share from other device makers. FreeStyle Libre is a key example. It can grow faster when more people with diabetes get coverage for continuous glucose monitoring, which tracks glucose through a sensor.
Diagnostics sells lab systems, rapid tests, point of care tests, and now cancer tests from Exact Sciences. This business can swing with testing demand. The addition of Exact Sciences brings high revenue, but investors are watching the heavy costs tied to the integration.
Nutrition and branded generic drugs add balance. Nutrition sells brands such as Ensure, Glucerna, PediaSure, and Pedialyte. Established Pharmaceuticals sells branded generic drugs in emerging markets. Across the company, profit can be hurt by price controls, rebates, competition, currency moves, and tax disputes.
What Abbott sells
FreeStyle Libre and Diabetes Care
Libre is Abbott's continuous glucose monitor for people with diabetes. The new Libre Duo adds ketone tracking, while the core business waits for new reimbursement to expand access.
Heart and neuromodulation devices
This includes rhythm management, electrophysiology, heart failure, vascular, structural heart, and neuromodulation devices. Electrophysiology is strong, while U.S. Structural Heart needs a sales reset.
Cancer Diagnostics
Exact Sciences brought Cologuard and Oncotype DX into Abbott. The unit added about $1.0 billion in second quarter sales.
Core, rapid, molecular, and point of care diagnostics
These tests support hospitals, labs, and clinics. Rapid and Molecular have seen weaker respiratory virus seasons, but core lab work remains stable.
Nutrition brands
Ensure, Glucerna, PediaSure, and Pedialyte serve adult and pediatric nutrition markets. Volumes have been weak across the U.S. and international markets.
Established Pharmaceuticals
This segment sells branded generic drugs in emerging markets. It grew 8.9 percent excluding foreign exchange in the first half of 2026.
Lingo wellness CGM
Lingo uses Abbott's glucose sensor technology for health and wellness consumers. It is an option on a broader market beyond diabetes care.
Q1 2026 sales mix
The mix uses Q1 2026 reportable segment sales from Abbott's Form 10-Q. Medical Devices is the largest piece, while new Exact Sciences revenue is changing the mix.
What could break the case
Nutrition recovery fades
Medium impact · High oddsNutrition sales fell 5.6 percent excluding foreign exchange in the first half of 2026 because volumes were lower in both U.S. pediatric and adult products. The segment failed to sustain the sequential recovery seen earlier in the year.
Exact Sciences debt load
High impact · Medium oddsAbbott funded the Exact Sciences deal mainly with about $20 billion of new long-term debt. That raises financial risk and limits flexibility. The deal must create enough profit to justify the balance sheet strain and high integration costs.
U.S. Structural Heart share loss
Medium impact · Medium oddsManagement said the U.S. mitral market problem is commercial execution, not price or product. Sales grew just 2.6 percent in the first half of 2026. Competitors have become tougher, and Abbott expects the fix to take time.
Libre reimbursement delay
High impact · Medium oddsLibre growth has settled into the high single digits while Abbott waits for the next major coverage expansion. If U.S. Type 2 Medicare coverage or international reimbursement takes longer than expected, the growth story could stay slower.
Global tax disputes
Medium impact · Medium oddsAbbott has active IRS disputes tied to how income is split between U.S. entities and foreign affiliates. The company also received a $413 million tax assessment from Malaysian authorities in July 2024, which it is currently appealing.
In one breath
What is Abbott Laboratories best known for?
Abbott is best known for medical devices, diagnostics, nutrition products, and branded generic drugs. Its FreeStyle Libre glucose monitor is one of its most important growth products.
Why did Abbott buy Exact Sciences?
Abbott bought Exact Sciences to enter cancer diagnostics. The deal adds Cologuard, Oncotype DX, and a massive new revenue stream that brought in about $1.0 billion in the second quarter of 2026 alone.
What is the main risk for Abbott stock?
The main risk is that the growth engines do not speed up enough to offset the new debt from Exact Sciences. Watch Libre reimbursement, Nutrition volumes, and the U.S. Structural Heart turnaround.
